Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine
We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was init...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2021-09, Vol.28 (5), p.285-288 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 288 |
---|---|
container_issue | 5 |
container_start_page | 285 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 28 |
creator | Torroba Sanz, Beatriz Mendez Martínez, Elena Cacho Asenjo, Elena Aquerreta Gonzalez, Irene |
description | We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome. |
doi_str_mv | 10.1136/ejhpharm-2019-002149 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8403773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564131918</sourcerecordid><originalsourceid>FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</originalsourceid><addsrcrecordid>eNqNkU1vFSEUhomxsc21_8AYEjftYiwMzDBsTEytH0mTGqtrwsC5HW4GGGHG5m795VJve_1YGFecwPO-nHNehJ5R8pJS1p7BZpgGnXxVEyorQmrK5SN0VBMuKilb_nhfN-0hOs7Z9aRhrJOcySfokHFet7xjR-j7R0heBwgzThD0iDN8XWDUUAoTg9Vpi-eIbVpuCqDN7GLAt24eMMTsQpwGNzqNdbA4b_MM3plS-GmOPuOTN58urq9Py0WwKXrALtjFgMX9FpdfZqcnF-ApOljrMcPx_blCX95efD5_X11evftw_vqy6hsq5qq2NeutXgspe7Y2DARQIwz0tm4N6UVHedsI1nWy0ZZw0mqoidFUUNYRbSRboVc732npPVhTZk56VFNyvkyponbqz5fgBnUTv6mOEyYEKwYn9wYplvbzrLzLBsax7C8uWdVNyymjknYFffEXuolLKvv9SbGWSlKOFeI7yqSYc4L1vhlK1F3O6iFndZez2uVcZM9_H2Qveki1AGc7oPeb_7UkvxT7Vv8p-QEdrses</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563619056</pqid></control><display><type>article</type><title>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Torroba Sanz, Beatriz ; Mendez Martínez, Elena ; Cacho Asenjo, Elena ; Aquerreta Gonzalez, Irene</creator><creatorcontrib>Torroba Sanz, Beatriz ; Mendez Martínez, Elena ; Cacho Asenjo, Elena ; Aquerreta Gonzalez, Irene</creatorcontrib><description>We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2019-002149</identifier><identifier>PMID: 34426483</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>adverse effects ; Allergies ; Antimicrobial agents ; Blood diseases ; Case Report ; chronic renal failure ; clinical pharmacy ; Creatinine ; Delirium ; dermatology ; Drug dosages ; Drug Hypersensitivity Syndrome - diagnosis ; Drug Hypersensitivity Syndrome - drug therapy ; Drug Hypersensitivity Syndrome - etiology ; Drug interactions ; Drug withdrawal ; Eosinophilia - chemically induced ; Eosinophilia - complications ; Eosinophilia - diagnosis ; Extracorporeal membrane oxygenation ; Hematology ; Hepatitis ; Humans ; intensive & critical care ; Kidney ; Male ; Mortality ; Myocarditis ; Pathophysiology ; Patients ; Psychotropic drugs ; Quetiapine Fumarate - adverse effects ; Side effects ; Skin ; Steroids ; Ventilators</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2021-09, Vol.28 (5), p.285-288</ispartof><rights>European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</citedby><cites>FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</cites><orcidid>0000-0003-2574-4076</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403773/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403773/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34426483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Torroba Sanz, Beatriz</creatorcontrib><creatorcontrib>Mendez Martínez, Elena</creatorcontrib><creatorcontrib>Cacho Asenjo, Elena</creatorcontrib><creatorcontrib>Aquerreta Gonzalez, Irene</creatorcontrib><title>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><addtitle>Eur J Hosp Pharm</addtitle><description>We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.</description><subject>adverse effects</subject><subject>Allergies</subject><subject>Antimicrobial agents</subject><subject>Blood diseases</subject><subject>Case Report</subject><subject>chronic renal failure</subject><subject>clinical pharmacy</subject><subject>Creatinine</subject><subject>Delirium</subject><subject>dermatology</subject><subject>Drug dosages</subject><subject>Drug Hypersensitivity Syndrome - diagnosis</subject><subject>Drug Hypersensitivity Syndrome - drug therapy</subject><subject>Drug Hypersensitivity Syndrome - etiology</subject><subject>Drug interactions</subject><subject>Drug withdrawal</subject><subject>Eosinophilia - chemically induced</subject><subject>Eosinophilia - complications</subject><subject>Eosinophilia - diagnosis</subject><subject>Extracorporeal membrane oxygenation</subject><subject>Hematology</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>intensive & critical care</subject><subject>Kidney</subject><subject>Male</subject><subject>Mortality</subject><subject>Myocarditis</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Psychotropic drugs</subject><subject>Quetiapine Fumarate - adverse effects</subject><subject>Side effects</subject><subject>Skin</subject><subject>Steroids</subject><subject>Ventilators</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1vFSEUhomxsc21_8AYEjftYiwMzDBsTEytH0mTGqtrwsC5HW4GGGHG5m795VJve_1YGFecwPO-nHNehJ5R8pJS1p7BZpgGnXxVEyorQmrK5SN0VBMuKilb_nhfN-0hOs7Z9aRhrJOcySfokHFet7xjR-j7R0heBwgzThD0iDN8XWDUUAoTg9Vpi-eIbVpuCqDN7GLAt24eMMTsQpwGNzqNdbA4b_MM3plS-GmOPuOTN58urq9Py0WwKXrALtjFgMX9FpdfZqcnF-ApOljrMcPx_blCX95efD5_X11evftw_vqy6hsq5qq2NeutXgspe7Y2DARQIwz0tm4N6UVHedsI1nWy0ZZw0mqoidFUUNYRbSRboVc732npPVhTZk56VFNyvkyponbqz5fgBnUTv6mOEyYEKwYn9wYplvbzrLzLBsax7C8uWdVNyymjknYFffEXuolLKvv9SbGWSlKOFeI7yqSYc4L1vhlK1F3O6iFndZez2uVcZM9_H2Qveki1AGc7oPeb_7UkvxT7Vv8p-QEdrses</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Torroba Sanz, Beatriz</creator><creator>Mendez Martínez, Elena</creator><creator>Cacho Asenjo, Elena</creator><creator>Aquerreta Gonzalez, Irene</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2574-4076</orcidid></search><sort><creationdate>20210901</creationdate><title>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</title><author>Torroba Sanz, Beatriz ; Mendez Martínez, Elena ; Cacho Asenjo, Elena ; Aquerreta Gonzalez, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b517t-2d23bdaf799b3fc3e7e1c7cebd26c0b781465738895ad0406ae20ca171380ac93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adverse effects</topic><topic>Allergies</topic><topic>Antimicrobial agents</topic><topic>Blood diseases</topic><topic>Case Report</topic><topic>chronic renal failure</topic><topic>clinical pharmacy</topic><topic>Creatinine</topic><topic>Delirium</topic><topic>dermatology</topic><topic>Drug dosages</topic><topic>Drug Hypersensitivity Syndrome - diagnosis</topic><topic>Drug Hypersensitivity Syndrome - drug therapy</topic><topic>Drug Hypersensitivity Syndrome - etiology</topic><topic>Drug interactions</topic><topic>Drug withdrawal</topic><topic>Eosinophilia - chemically induced</topic><topic>Eosinophilia - complications</topic><topic>Eosinophilia - diagnosis</topic><topic>Extracorporeal membrane oxygenation</topic><topic>Hematology</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>intensive & critical care</topic><topic>Kidney</topic><topic>Male</topic><topic>Mortality</topic><topic>Myocarditis</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Psychotropic drugs</topic><topic>Quetiapine Fumarate - adverse effects</topic><topic>Side effects</topic><topic>Skin</topic><topic>Steroids</topic><topic>Ventilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torroba Sanz, Beatriz</creatorcontrib><creatorcontrib>Mendez Martínez, Elena</creatorcontrib><creatorcontrib>Cacho Asenjo, Elena</creatorcontrib><creatorcontrib>Aquerreta Gonzalez, Irene</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torroba Sanz, Beatriz</au><au>Mendez Martínez, Elena</au><au>Cacho Asenjo, Elena</au><au>Aquerreta Gonzalez, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><addtitle>Eur J Hosp Pharm</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>28</volume><issue>5</issue><spage>285</spage><epage>288</epage><pages>285-288</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>We describe a Caucasian man in his late 60s who was admitted to the intensive care unit (ICU) with a history of cardiogenic shock secondary to an acute myocardial infarction. The patient’s baseline serum creatinine levels were 0.9–1 mg/dL. On day 7 of the admission treatment with quetiapine was initiated due to a delirium episode. The next day the patient developed an erythematous-maculopapular rash and fever, with eosinophilia in the blood count. Over the following days the patient experienced an acute deterioration of kidney function requiring continuous renal replacement therapy. The skin lesions and eosinophilia resolved after withdrawal of quetiapine and systemic steroid therapy was administered. The patient was discharged from the ICU with a serum creatinine level of 2.6 mg/dL. Three months later, blood tests showed no recovery of the kidney function. According to the Naranjo adverse drug reaction probability scale, this event would be classified as 'probable' DRESS syndrome and, based on the RegiSCAR scoring system, was classified as 'definite' DRESS syndrome.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>34426483</pmid><doi>10.1136/ejhpharm-2019-002149</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-2574-4076</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2021-09, Vol.28 (5), p.285-288 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8403773 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | adverse effects Allergies Antimicrobial agents Blood diseases Case Report chronic renal failure clinical pharmacy Creatinine Delirium dermatology Drug dosages Drug Hypersensitivity Syndrome - diagnosis Drug Hypersensitivity Syndrome - drug therapy Drug Hypersensitivity Syndrome - etiology Drug interactions Drug withdrawal Eosinophilia - chemically induced Eosinophilia - complications Eosinophilia - diagnosis Extracorporeal membrane oxygenation Hematology Hepatitis Humans intensive & critical care Kidney Male Mortality Myocarditis Pathophysiology Patients Psychotropic drugs Quetiapine Fumarate - adverse effects Side effects Skin Steroids Ventilators |
title | Permanent renal sequelae secondary to drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by quetiapine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T15%3A23%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Permanent%20renal%20sequelae%20secondary%20to%20drug%20reaction%20with%20eosinophilia%20and%20systemic%20symptoms%20(DRESS)%20syndrome%20induced%20by%20quetiapine&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Torroba%20Sanz,%20Beatriz&rft.date=2021-09-01&rft.volume=28&rft.issue=5&rft.spage=285&rft.epage=288&rft.pages=285-288&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2019-002149&rft_dat=%3Cproquest_pubme%3E2564131918%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563619056&rft_id=info:pmid/34426483&rfr_iscdi=true |